Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

AUPH

Get informed when a big investor buys or sells

+ Follow
Market Cap$2.24B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Aurinia Pharmaceuticals IncAurinia Pharmaceuticals Inc7.1-51%8.40.1
$16.00

Target Price by Analysts

5.1% downsideAurinia Pharmaceuticals Target Price DetailsTarget Price
$7.01

Current Fair Value

58.4% downside

Overvalued by 58.4% based on the discounted cash flow analysis.

Share Statistics

Market cap$2.24 Billion
Enterprise Value$2.13 Billion
Dividend Yield$- (-)
Earnings per Share$2.14
Beta1.41
Outstanding Shares130,081,000

Return

Return on Equity51.09%ROE
Return on Assets39.65%
Return on Invested Capital23.56%

Valuation & Multiples

P/E Ratio7.14P/E Ratio
PEG9.67PEG
Price to Sales8.43Price to Sales
Price to Book Ratio4.22Price to Book Ratio
Enterprise Value to Revenue6.85
Enterprise Value to EBIT13.09
Enterprise Value to Net Income6
Total Debt to Enterprise0.03
Debt to Equity0.12Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 6, 2026
EPS Estimate
$0.24
Average shareholder expectation
Revenue Estimate
$80.45 M
Average shareholder expectation

Next Earnings Call

Expected Date
October 29, 2026
EPS Estimate
$0.24
Average shareholder expectation
Revenue Estimate
$82.86 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio3.5381▲ 273.49%
Total Calls380,600▲ 4.05%
Total Puts1,346,600▲ 358.34%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %59.96%▲ 4.06%
Total Invested$1.35B▲ 22.80%
Investors Holding294▲ 18.00%

ESG Score

No data

About Aurinia Pharmaceuticals Inc

CEO: Peter Greenleaf